One Thing is crystal clear in Tefferi's abstract that seems to be lost in all this back and forth. Imetelstat appears to be showing a very powerful anticancer effect in Myelofibrosis.
So Imetelstat did not shrink the spleen size by 50% at the time of the abstract, show me another drug that has had this dramatic effect in Myelofibrosis in killing the cancer in the bone marrow. I know I am not as educationally gifted as some on this board, but when 2 patients go from transfusion depend status to transfusion independent status one should consider the possibility that something very valuable is going on in the bone marrow of these cancer patients.
If Imetelstat responses are as duable as it's responses in Essential thrombocythemia, then Imetelstat could be a best in class agent in Myelofibrosis.
If Tefferi shows responses in his AML cohort Imetelstat could be a billion dollar opportunity.
Market Data 
Markets 
AI
